Plain-English translation of NCT06494540 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world observational study tracking patients with advanced non-squamous lung cancer who are starting treatment with tremelimumab, durvalumab, and platinum-based chemotherapy (TDC). Instead of randomly assigning people to different treatments, researchers will follow patients in routine clinical practice to see how well this medication combination works and how genetic factors affect the results.
Advanced lung cancer patients with certain genetic changes often have limited treatment options and unpredictable outcomes. This study aims to better understand which patients benefit most from this three-drug treatment based on their specific genetic profile, so doctors can make more personalized treatment decisions in the future.
You likely qualify if…
You likely don't qualify if…
You would continue receiving your standard cancer treatment from your regular doctor as planned—no extra medications or procedures are being tested. The study team will collect information from your medical records, including how well the treatment is working, your genetic test results, and how you are doing over time. You will likely have visits with your cancer doctor on a normal schedule, and the study simply documents what happens during your routine care.
AI-generated summary from trial data · Sep 2, 2026 · Not medical advice
Germany